IGF Oncology is a pioneering brand dedicated to developing innovative cancer drugs that offer enhanced effectiveness and reduced side effects compared to conventional chemotherapy treatments. With a focus on improving patient outcomes, IGF Oncology's lead drug, IGF-MTX, is a groundbreaking conjugate of methotrexate, a widely-used chemotherapy drug, and a targeting protein. Animal studies have showcased its superiority, demonstrating that IGF-MTX is 15 times more effective than methotrexate and significantly lowers side effects.

Phase 1 clinical trials have also yielded promising results, even in heavily pre-treated advanced tumors that had progressed on approved drugs. Unlike traditional chemotherapy drugs, IGF-MTX exhibits minimal side effects, with no decrease in blood cell counts. The drug is presently undergoing a second clinical trial at the prestigious Mayo Clinic for the treatment of myelodysplastic syndrome (MDS), with early findings further validating its efficacy and low side effects.

IGF Oncology also boasts a robust pipeline of targeted cancer drugs, cementing their commitment to revolutionizing cancer treatment